简介：·Thetherapeuticeffectofselenium(Se)hasalreadybeenproveninthyroiddiseaseandthyroidassociatedophthalmopathy(TAO).InspiteofclearscientificproofofitsbenefitsinTAO,thereappearstobenoclearagreementamongthecliniciansregardingitsoptimumdose,durationofthetreatment,efficacyandsafetytodate.Inthisreview,theauthorsummarisesthefindingsof135Englishlanguagearticlespublishedonthissubjectoverthepastfourdecadesfrom1973to2013.TheregulationandmetabolismofthyroidhormonesrequireasteadysupplyofSeandrecentstudieshaverevealedseveralpossiblemechanismsbywhichSeimprovestheseverityofthyroiddiseaseandTAO.Thesemechanismsinclude1)inhibitoryeffectofHLA-DRmoleculeexpressiononthyrocytes;2)profoundreductionsofthyroidstimulatinghormone(TSH)receptorantibodies(TSHR-Ab)andTPOantibodies(TPO-Ab);3)preventionofdysregulationofcell-mediatedimmunityandBcellfunction;4)neutralisingreactiveoxygenspecies(ROS)andinhibitionofredoxcontrolprocessesrequiredfortheactivation,differentiationandactionoflymphocytes,macrophages,neutrophils,naturalkillercellsinvolvedinbothacuteandchronicorbitalinflammationinTAO;5)inhibitionofexpressionofproinflammatorycytokinesand6)inhibitionofprostaglandinandleukotrienesynthesis.AnincreasedoxidativestresshasbeenobservedinbothacuteandchronicphasesofthyroiddiseasewithraisedtissueconcentrationsofROS.ThebenefitsofSesupplementationinindividualswithTAOappeartobeproportionatetothedegreeofsystemicactivityofthethyroiddisease.ThemaximalbenefitofSesupplementationisthereforeseeninthesubjectswhoarehyperthyroid.RestorationofeuthyroidismisoneofthemaingoalsinthemanagementofTAOandwhenanti-thyroiddrugsarecombinedwithSe,thepatientswithGraves’disease(GD)andautoimmunethyroiditis(AIT)achievedeuthyroidismfasterthanthosetreatedwithanti-thyroiddrugsalone.SestatusofnormaladulthumanscanvarywidelyandSe

简介：甲状腺癌是临床上常见的恶性肿瘤，约占全身肿瘤的1，3％，占头颈部肿瘤的5．1％。病理类型分为乳头状腺癌（60％～80％）、滤泡状腺癌（20％）、髓样癌（3％-10％）及未分化癌（15％）。分化型甲状腺癌包括乳头状腺癌和滤泡状腺癌，发病率高，生长缓慢，恶性程度较低。由于基层医院在术前诊断方面的欠缺，术中往往没有冷冻病理检查，造成手术不规范，需要再次手术修正。现对我院52例需再次手术的分化型甲状腺癌病例进行分析，总结如下。

简介：目的：构建表达小鼠CD4＋T细胞钙支架蛋白AHNAK1的短发夹RNA（shorthairpinRNA,shRNA）慢病毒载体,并研究其对小鼠甲状腺相关性眼病（thyroid-associatedophthalmopathy,TAO）的抑制效应。方法：设计并筛选对AHNAK1具有良好干扰效力的shRNA序列,慢病毒载体包装干扰序列,感染小鼠CD4＋T细胞,检测AHNAK1静默对T细胞功能的抑制作用,采用实验动物模型观察AHNAK1体内抑制甲状腺相关性眼病的效果。结果：成功筛选出具有良好干扰效力的shRNA,并包装入慢病毒。病毒滴度为1.0伊106TU/mL,转染慢病毒的CD4＋T细胞展现出失能倾向,抑制炎症免疫反应;在动物模型中抑制T细胞中AHNAK1表达可以有效控制甲状腺眼病的发生发展,显著降低治疗组T细胞中IL-2、IL-1茁和IFN-酌的表达。结论：成功构建了表达小鼠AHNAK1shRNA的慢病毒,具有抑制T细胞分泌IL-2、IL-1茁和IFN-酌的表达效应,能够有效抑制甲状腺眼病的发生发展。